Viewing Study NCT00004438



Ignite Creation Date: 2024-05-05 @ 10:23 AM
Last Modification Date: 2024-10-26 @ 9:04 AM
Study NCT ID: NCT00004438
Status: COMPLETED
Last Update Posted: 2015-03-25
First Post: 1999-10-18

Brief Title: Leuprolide in Treating Adults With Hypogonadotropism
Sponsor: University of Chicago
Organization: FDA Office of Orphan Products Development

Study Overview

Official Title: Study of Leuprolide in Adults With Hypogonadotropism
Status: COMPLETED
Status Verified Date: 1998-06
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: RATIONALE Hypogonadotropism is an abnormal condition caused by decreased production of gonadotropins a group of hormones that stimulate the parts of the reproductive system that produce and release eggs from the ovaries or sperm from the testicles Leuprolide may stimulate the production of gonadotropins and be effective in increasing testosterone in men and inducing ovulation in women

PURPOSE Clinical trial to study the effectiveness of leuprolide in treating adults who have hypogonadotropism
Detailed Description: PROTOCOL OUTLINE Male patients receive leuprolide subcutaneously every 5 days for up to one year and are followed at weeks 4 6 8 and 12 then every 2 months

Female patients receive leuprolide subcutaneously on days 1 6 and possibly 11 Patients are followed 2 months after the last injection

Completion date provided represents the completion date of the grant per OOPD records

Study Oversight

Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
Secondary ID Type Domain Link
UCCH-FDR001473 None None None
UCCH-8451 None None None